Asset Details
Do you wish to reserve the book?
Pegcetacoplan: First Approval
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pegcetacoplan: First Approval
Do you wish to request the book?
Pegcetacoplan: First Approval
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pegcetacoplan: First Approval
2021
Overview
Pegcetacoplan (Empaveli™) is a PEGylated pentadecapeptide developed by Apellis Pharmaceuticals for the treatment of complement-mediated diseases. It binds to complement component 3 (C3) and its activation fragment C3b, controlling the cleavage of C3 and the generation of the downstream effectors of complement activation and thus both C3b-mediated extravascular haemolysis and terminal complement-mediated intravascular haemolysis. Pegcetacoplan is the first C3-targeted paroxysmal nocturnal haemoglobinuria (PNH) therapy to be approved (in May 2021) in the USA, where it is indicated for the treatment of adults with PNH, including those switching from C5 inhibitor therapy with eculizumab and ravulizumab. A regulatory assessment of pegcetacoplan for the treatment of PNH is currently underway in the EU and Australia. Pegcetacoplan is also being investigated as a therapeutic option in other complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy and autoimmune haemolytic anaemia. The recommended dosage regimen of pegcetacoplan is 1080 mg twice weekly, administered as a subcutaneous infusion via an infusion pump with a ≥ 20 mL reservoir. This article summarizes the milestones in the development of pegcetacoplan leading to this first approval for the treatment of adults with PNH.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Adults
/ Amyotrophic lateral sclerosis
/ Anemia
/ Anemia, Hemolytic, Autoimmune - drug therapy
/ Complement C3 - antagonists & inhibitors
/ Complement C3b - antagonists & inhibitors
/ Complement Inactivating Agents - pharmacology
/ Complement Inactivating Agents - therapeutic use
/ Geographic Atrophy - drug therapy
/ Glomerulonephritis - drug therapy
/ Hemoglobinuria, Paroxysmal - drug therapy
/ Humans
/ Medicine
/ Patients
/ Peptides
/ Peptides, Cyclic - pharmacology
